Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
621 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleEffect and Mechanism of ALPPS Operation on Liver Regeneration
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Haitao Zhao, MD
See details and how to joinNCT07142213 - Phase 2Taking peopleA Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
- Where
- Wuhan
- Age
- 18 years to 80 years
- People
- 37
- Run by
- Yongjun Chen
See details and how to joinNCT07135544 - Phase 1Taking peopleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- Where
- Zhengzhou
- Age
- 18 years to 75 years
- People
- 21
- Run by
- GONGCHU Biotechnology Co., Ltd
See details and how to joinNCT06508307 - No phaseTaking peopleChina Liver Cancer Clinical Registry Cohort Database (HEAL)
- Where
- Anqing, Bengbu, Bozhou, Chizhou, Chuzhou, Fuyang, Hefei, Huaibei, Huainan, Huangshan City, Lu'an, Suzhou, Tongling, Wuhu, Xuancheng, Zhengzhou
- Age
- 18 years and over
- People
- 10,000
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT06777485 - Phase 2Not yet taking people in ChinaA Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 48
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07131501 - Phase 1Taking peopleImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
- Where
- Wuhan
- Age
- 18 years to 70 years
- People
- 16
- Run by
- Zhiyong Huang
See details and how to joinNCT06084299 - Phase 2Taking peopleTauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Where
- Shanghai
- Age
- 18 years and over
- People
- 141
- Run by
- Fudan University
See details and how to joinNCT07100392 - No phaseTaking peopleTACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
- Where
- Shanghai
- Age
- 18 years and over
- People
- 50
- Run by
- Fudan University
See details and how to joinNCT07100405 - Phase 2Taking peopleHAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
- Where
- Shanghai
- Age
- 18 years and over
- People
- 45
- Run by
- Fudan University
See details and how to joinNCT07105748 - No phaseTaking peopleImpact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Zhiyong Huang
See details and how to joinNCT06280313 - No phaseTaking peopleLocoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 240
- Run by
- Sun Yat-sen University
See details and how to joinNCT06323382 - No phaseTaking peopleTACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 32
- Run by
- Sun Yat-sen University
See details and how to joinNCT06740370 - Phase 1/2Taking peopleAutologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Zhejiang University
See details and how to joinNCT07123545 - No phaseTaking peopleCT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
- Where
- Yangzhou
- Age
- 18 years and over
- People
- 5
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT05433467 - Phase 2Taking peopleCryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 56
- Run by
- Fudan University
See details and how to joinNCT07070700 - Phase 2Taking peopleExploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 59
- Run by
- Sir Run Run Shaw Hospital
See details and how to joinNCT07105852 - No phaseNot yet taking people in China29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Where
- Chaoyang, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
- Age
- 18 years and over
- People
- 350
- Run by
- Junjie Xu
See details and how to joinNCT07100236 - No phaseTaking peopleAn Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 308
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07101237 - Phase 2Not yet taking people in ChinaA Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
- Where
- Beijing
- Age
- 18 years and over
- People
- 90
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07099794 - Phase 2Taking peoplePerioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 43
- Run by
- Sun Yat-sen University
See details and how to joinNCT06031285 - No phaseTaking peoplePredicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
- Where
- Wuhan
- Age
- 18 years and over
- People
- 350
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07059936 - Phase 1Taking peopleApplication of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
- Where
- Chengdu
- Age
- 18 years and over
- People
- 15
- Run by
- West China Hospital
See details and how to joinNCT07077356 - No phaseNot yet taking people in ChinaReal-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Where
- Xi'an
- Age
- 18 years to 70 years
- People
- 1,500
- Run by
- First Affiliated Hospital Xi'an Jiaotong University
See details and how to joinNCT07079150 - Phase 2Not yet taking people in ChinaTauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
- Where
- Wuhan
- Age
- 18 years to 80 years
- People
- 300
- Run by
- Tongji Hospital
See details and how to joinNCT07064668 - No phaseTaking peopleThe Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 100
- Run by
- Sun Yat-sen University
See details and how to joinNCT07064681